TREPROSTINIL INJECTION 10 MG
TREPROSTINIL (TREPROSTINIL SODIUM) : 10 MG · DIN 02523884 · DR REDDY'S LABORATORIES LTD
Health Canada status: APPROVED
What is TREPROSTINIL INJECTION?
TREPROSTINIL INJECTION 10 MG contains TREPROSTINIL (TREPROSTINIL SODIUM) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02523884, held by DR REDDY'S LABORATORIES LTD, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as approved, status dated 30-Dec-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02523884 |
|---|---|
| Brand name | TREPROSTINIL INJECTION |
| Generic / active ingredient | TREPROSTINIL (TREPROSTINIL SODIUM) : 10 MG |
| Manufacturer | DR REDDY'S LABORATORIES LTD |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B01AC21 TREPROSTINIL |
| AHFS class | 48:48.00 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 30-Dec-2021 |
What can be used instead?
Other Canadian products sharing ATC code B01AC21 TREPROSTINIL. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| REMODULIN | 1 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246552 |
| REMODULIN | 10 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246555 |
| REMODULIN | 2.5 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246553 |
| REMODULIN | 5 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246554 |
| TREPROSTINIL INJECTION | 1 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523841 |
| TREPROSTINIL INJECTION | 2.5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523868 |
| TREPROSTINIL INJECTION | 5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523876 |
Who else supplies TREPROSTINIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TREPROSTINIL appears in 105 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.